Press Releases

Press Releases

The information contained in press releases should be considered accurate only as of the date of the press release. We disclaim any obligation to supplement or update the information in these press releases.

Year
News

29 June, 2020

Incyte Announces Approval of Tabrecta™ (capmatinib) in Japan for the Treatment of Patients with Advanced Non-Small Cell Lung Cancer with METex14

17 June, 2020

Incyte Investor Conference Update

15 June, 2020

Incyte Launches New Global Responsibility Section on Incyte.com

03 June, 2020

Incyte to Present at Upcoming Investor Conferences

29 May, 2020

Interim Data from the Open Label Phase 2 OPTIC Study of Iclusig® (ponatinib) for Chronic Phase-CML Presented at the ASCO and EHA Virtual Meetings

21 May, 2020

Incyte to Present at Upcoming Investor Conference

20 May, 2020

Incyte and MorphoSys Announce the Validation of the European Marketing Authorization Application for Tafasitamab

14 May, 2020

Data from Incyte’s Oncology Portfolio Accepted for Presentation at the ASCO and EHA Virtual Meetings

14 May, 2020

MorphoSys and Incyte Announce Long-term Follow-up Results from L-MIND Study of Tafasitamab in Patients with r/r DLBCL

06 May, 2020

Incyte Announces FDA Approval of Tabrecta™ (capmatinib) for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with METex14

of 1 2 3 4 Next page
 

For Media Inquiries

Catalina Loveman
Executive Director, Public Affairs

+1 302.498.6171 | media@incyte.com


For Investor Relations

Michael Booth, D.Phil.
Divisional VP of Investor Relations and Corporate Responsibility

Phone: 302.498.5914

Email: mbooth@incyte.com

Lauren Ayala, MBA
Senior Director, Investor Relations & Corporate Responsibility

Phone: 302.498.6141

Email: layala@incyte.com

Christine Chiou
Senior Director, Investor Relations

Phone: 302.274.4773

Email: cchiou@incyte.com